Anxiety Disorders (September)

Date of Issue: 09/01/2013 | Volume: 11 | Number: 9

Issue Links:Learning Objectives | Editorial Information

Teaser to be posted soon.

In This Issue

Article

Antipsychotics and Anticonvulsants for Anxiety Disorders

Topics: Anxiety Disorder

We know how frequently our patients complain of anxiety. Anxiety disorders are common, chronic conditions. They also increase the risk for mood and substance disorders, and complaints of anxiety are found in a wide range of other psychiatric and medical conditions, as well.

Read More
Article

Table - FDA Approved Medications for Anxiety

Topics: Anxiety Disorder

Read More
Expert Q&A

Anxiety Disorders in DSM-5 and Beyond

Topics: Anxiety Disorder

Dr Daniel Pine, chief of the section on Development and Affective Neuroscience at the NIMH and chair of the DSM-5 Work Group on Child and Adolescent Psychiatric Disorders discusses anxiety disorders in the current and future state of anxiety disorder research and practice.

Read More
Research Update

Is Dose Reduction the Ideal Strategy after First Episode of Psychosis?

Topics: Research Updates

What’s the optimal treatment for a first episode of psychosis? Few would argue against antipsychotic treatment, but what happens when the patient achieves remission?

Read More
News of Note

Fetzima Approved for Depression

Topics: News of Note

In July 2013, the FDA approved the SNRI Fetzima (levomilnacipran) for major depressive disorder (MDD) in adults (Forest Laboratories, Inc). The efficacy of Fetzima at doses 40 mg to 120 mg once daily was established in three, eight-week, randomized, double-blind, placebo-controlled studies in adults diagnosed MDD.

Read More